Shanghai Jianxin equity is a Cci Capital Ltd focused on healthcare industry risk investment fund, has a professional investment team, the team has rich medical and financial investment, management and entrepreneurial experience, can make prospective investment layout according to the development trend of the industry, creating value for enterprises and investors. The company has a team of nearly 20 professional investment team, they were from medical institutions and financial class at home and abroad, with senior biomedical and financial professional background, have rich human resources in the field, the trend of development, familiar with domestic and international bio pharmaceutical industry research and development dynamics, can focus on the invested enterprise demand for product development, industrialization, management and financial investment and a full range of value-added services.
Isabers is a provider of advanced semiconductor integration technology and products, which can achieve inter-generational fusion of semiconductor materials and advanced packaging and can effectively solve the pain points of low yield, high cost, and limited performance of advanced semiconductor materials or devices, thus accelerating the development of the domestic semiconductor industry and quickly seizing the strategic high ground of international market competition.
Meike Solar focuses on the research and development of solar photovoltaic polycrystalline silicon wafers and operates integrated monitoring systems and equipment to facilitate intelligent manufacturing processes, permitting itself to make products efficiently at a reduced cost.
Weishi Energy is a hydrogen fuel cell product research and development manufacturer, focusing on the market operation of hydrogen fuel cell technology, and is committed to promoting the low-carbon sustainable development of human energy. It is mainly engaged in the research and development, production and sales of hydrogen fuel cell products. At present, Weishi Energy has deployed five R&D centers in Shanghai, Baoding, Japan, Germany, and Canada. It has established a culturally diverse and technologically advanced R&D team, and strictly follows the V model development process to create vehicle-level fuel cell power systems and components. The company's main products include fuel cell engines, electric stacks, 35MPa/70MPa on-board hydrogen systems, bottle valves and pressure reducing valves, etc.
Genecast offers DNA testing of tumors and gene-based medicine guidance. The company claims expertise in lung, colon, liver and breast cancers. Genecast plans to use the proceeds for further research and clinical trials, as well as expanding distribution channels.
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.
Percutek Therapeutics specializes in the research, development, and manufacturing of cardiovascular interventional medical devices. The company focuses on Class III minimally invasive devices aimed at diagnosing and treating a range of cardiovascular conditions. Its product portfolio includes devices for various applications, such as aortic, peripheral, and coronary interventions, as well as nerve access. By prioritizing patient safety and clinical efficacy, Percutek Therapeutics is committed to delivering high-quality solutions that enhance the treatment of vascular diseases, thereby supporting both healthcare providers and patients in achieving better health outcomes.
Leads Biolabs is a biotechnology company focused on developing innovative antibody-based therapeutics to address unmet medical needs in oncology and immunological diseases. Founded in 2014 and headquartered in China, the company has established a strong research and development pipeline featuring over ten projects centered on monoclonal and bispecific antibodies for cancer immunotherapy. By concentrating on tumor immunotherapy, Leads Biolabs aims to enhance treatment outcomes and access for patients globally, thereby improving their medical conditions and overall quality of life.
InnoCare is a biopharmaceutical company based in China, focused on discovering, developing, and commercializing innovative treatments for cancer and autoimmune diseases. The company boasts a skilled scientific team with extensive experience in drug innovation from both the U.S. and China, supported by an accomplished Scientific Advisory Board comprised of experts from prominent universities, hospitals, and the pharmaceutical sector. InnoCare's product pipeline includes several key therapies, such as orelabrutinib, ibrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune disorders. The company is also dedicated to addressing autoimmune diseases linked to abnormal B-cell or T-cell functions, positioning itself as a leader in advancing medical treatments and tackling complex health challenges.
Leads Biolabs is a biotechnology company focused on developing innovative antibody-based therapeutics to address unmet medical needs in oncology and immunological diseases. Founded in 2014 and headquartered in China, the company has established a strong research and development pipeline featuring over ten projects centered on monoclonal and bispecific antibodies for cancer immunotherapy. By concentrating on tumor immunotherapy, Leads Biolabs aims to enhance treatment outcomes and access for patients globally, thereby improving their medical conditions and overall quality of life.
Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CART antibodies. .
Eastern Biotech is a pharmaceutical product development and manufacturing company focused on advancing treatments for diabetes and obesity. The company engages in medical research to develop innovative biotechnology solutions, including humanized monoclonal antibodies and therapeutic vaccines. In addition to addressing diabetes, Eastern Biotech also works on therapies for immune diseases, malignant tumors, and various cancers, contributing to a broader array of healthcare challenges. Through its commitment to research and development, Eastern Biotech aims to improve patient outcomes and enhance treatment options in the field of medicine.
Huadao Biopharma is a biomedical company focused on cellular immunotherapy, specifically in the field of oncology. The company develops advanced CAR-T (chimeric antigen receptor-T) cell technologies, utilizing methods such as bacteria fermentation engineering and virus purification techniques. Huadao Biopharma also specializes in T cell acquisition and cell harvesting, offering healthcare practitioners valuable research resources and expertise. Its primary aim is to enhance treatment options for conditions like acute lymphoblastic leukemia and other related diseases, contributing to advancements in cancer therapies.
Leads Biolabs is a biotechnology company focused on developing innovative antibody-based therapeutics to address unmet medical needs in oncology and immunological diseases. Founded in 2014 and headquartered in China, the company has established a strong research and development pipeline featuring over ten projects centered on monoclonal and bispecific antibodies for cancer immunotherapy. By concentrating on tumor immunotherapy, Leads Biolabs aims to enhance treatment outcomes and access for patients globally, thereby improving their medical conditions and overall quality of life.
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.
LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.
Jia.com (齐家网) is an interior designing platform that focuses mainly on home decoration. Launched in March 2005, Jia.com was originated by Shanghai Qijia Information Technology Co., Ltd. and the core business of the company includes products such as decorations, building materials, furniture, appliances, mass consumer goods, and more. By June, 2010, the number of registered members had reached 1.8 million and it had held more than 2 thousand group buying events in renovation, construction materials, home decoration, and wedding cumulatively, providing group buying services to more than 5 million customers. Nearly 12,000 businesses and 15,000 brands have joined the network group-buying platform, and the annual valid orders are over 1,020,000, with the total out-put value of more than 3.2 billion Yuan.
Hair & Yard is a hair product manufacturing company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.